Abstract:ABSTRACT The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant protein vaccines have been widely used in the real world and shown good protective effects. A vaccine prepared from the ancestral SARS-CoV-2 receptor-binding domain (RBD) homodimer was previously made a candidate in view of its effectiveness in rodents and nonhuman primates. Here, we report that the RBD homodimers of ancestral SARS-CoV-2 as well as the variant RBD dimers from the Beta, Delta, Lambda, Omicron, and Omicron sublineages, which were rapidly prepared using our universal dimeric protein platform, elicit both strong immunogenicity and good protection in vivo . The ancestral RBD vaccine was verified to provide cross-protection against the SARS-CoV-2 Delta variant from lethal challenge. A heterogeneous booster with Omicron BA.1 dimeric RBD vaccine based on a two-dose ancestral vaccine prime reduced the viral loads in Omicron BA.1 virus-challenged animals. In addition, vaccines prepared from dimeric Omicron XBB.1.5 RBD completely protected the mice from lethal challenge by Omicron XBB.1.16 and reduced the viral infection in the respiratory tract of Syrian hamsters. Thus, RBD homodimer vaccines can confer good protection against SARS-CoV-2 and its variants when used in homogeneous or heterogeneous boosting schemes. IMPORTANCE Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants achieved immune escape and became less virulent and easily transmissible through rapid mutation in the spike protein, thus the efficacy of vaccines on the market or in development continues to be challenged. Updating the vaccine, exploring compromise vaccination strategies, and evaluating the efficacy of candidate vaccines for the emerging variants in a timely manner are important to combat complex and volatile SARS-CoV-2. This study reports that vaccines prepared from the dimeric receptor-binding domain (RBD) recombinant protein, which can be quickly produced using a mature and stable process platform, had both good immunogenicity and protection in vivo and could completely protect rodents from lethal challenge by SARS-CoV-2 and its variants, including the emerging Omicron XBB.1.16, highlighting the value of dimeric recombinant vaccines in the post-COVID-19 era.

Effect of adjuvanting RBD-dimer-based subunit COVID-19 vaccines with Sepivac SWE TM

A Bivalent COVID-19 Vaccine Based on Alpha and Beta Variants Elicits Potent and Broad Immune Responses in Mice against SARS-CoV-2 Variants

Effect of Different Adjuvants on Immune Responses Elicited by Protein-Based Subunit Vaccines against SARS-CoV-2 and Its Delta Variant

Choice of adjuvant and antigen composition alters the immunogenic profile of a SARS-CoV-2 subunit vaccine

Low-Dose SARS-CoV-2 S-Trimer with an Emulsion Adjuvant Induced Th1-Biased Protective Immunity

Adjuvants to the S1-subunit of the SARS-CoV-2 spike protein vaccine improve antibody and T cell responses and surrogate neutralization in mice

A Novel Polymer Nanoparticle Polydimethyl Diallyl Ammonium Chloride as An Adjuvant Enhances the Immune Response of SARS-CoV-2 Subunit Vaccine

A two-dose optimum for recombinant S1 protein-based COVID-19 vaccination

Protection of the receptor binding domain (RBD) dimer against SARS-CoV-2 and its variants

[Preparation and immungenicity of recombinant protein containing intramolecular adjuvant in SARS-CoV-2 RBD domain].

Use of Adjuvant Compositions Based on Squalene Ensures Induction of Neutralizing Antibodies against SARS-CoV-2

Robust and protective immune responses induced by heterologous prime‐boost vaccination with DNA‐protein dimeric RBD vaccines for COVID‐19

An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice

Tuning the immune response: sulfated archaeal glycolipid archaeosomes as an effective vaccine adjuvant for induction of humoral and cell-mediated immunity towards the SARS-CoV-2 Omicron variant of concern

RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates

Efficacy of a stable broadly protective subunit vaccine platform against SARS-CoV-2 variants of concern

SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung

Alum/CpG adjuvant promotes immunogenicity of inactivated SARS-CoV-2 Omicron vaccine through enhanced humoral and cellular immunity

Proanthocyanidins-based Adjuvant for Enhanced Immune Responses of SARS-CoV-2 Subunit Vaccine

A Novel Targeted RIG-I Receptor 5'Triphosphate Double Strain RNA-Based Adjuvant Significantly Improves the Immunogenicity of the SARS-CoV-2 Delta-Omicron Chimeric RBD-Dimer Recombinant Protein Vaccine

Aluminum hydroxide and immunostimulatory glycolipid adjuvant combination for enhanced COVID-19 subunit vaccine immunogenicity